ValuEngine cut shares of Juniper Pharmaceuticals (NASDAQ:JNP) from a hold rating to a sell rating in a report published on Friday.

Separately, HC Wainwright reaffirmed a neutral rating on shares of Juniper Pharmaceuticals in a research note on Monday, November 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The company has an average rating of Hold and an average price target of $23.00.

Shares of Juniper Pharmaceuticals (NASDAQ:JNP) traded up $0.12 during trading on Friday, reaching $5.03. 33,247 shares of the company were exchanged, compared to its average volume of 38,846. The stock has a market cap of $55.88, a price-to-earnings ratio of 7.66 and a beta of 0.05. Juniper Pharmaceuticals has a 1 year low of $3.65 and a 1 year high of $6.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.00 and a quick ratio of 1.68.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Algert Global LLC lifted its stake in Juniper Pharmaceuticals by 20.4% in the 3rd quarter. Algert Global LLC now owns 144,565 shares of the specialty pharmaceutical company’s stock worth $658,000 after purchasing an additional 24,530 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Juniper Pharmaceuticals by 19.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 86,866 shares of the specialty pharmaceutical company’s stock worth $395,000 after purchasing an additional 13,991 shares in the last quarter. Macquarie Group Ltd. purchased a new position in Juniper Pharmaceuticals in the 3rd quarter worth approximately $129,000. Goldman Sachs Group Inc. lifted its stake in Juniper Pharmaceuticals by 3.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 21,735 shares of the specialty pharmaceutical company’s stock worth $110,000 after purchasing an additional 715 shares in the last quarter. Finally, Nationwide Fund Advisors lifted its stake in Juniper Pharmaceuticals by 5,500.0% in the 2nd quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock worth $283,000 after purchasing an additional 55,000 shares in the last quarter. 36.39% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Juniper Pharmaceuticals (JNP) Lowered to Sell at ValuEngine” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/juniper-pharmaceuticals-jnp-lowered-to-sell-at-valuengine/1740021.html.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Receive News & Ratings for Juniper Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.